NCT02131818

Brief Summary

The purpose of this study is to determine amoxicillin is effective in the prevention of wound infection in normal labor.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started May 2014

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 28, 2014

Completed
3 days until next milestone

Study Start

First participant enrolled

May 1, 2014

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 6, 2014

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2015

Completed
Last Updated

December 3, 2015

Status Verified

December 1, 2015

Enrollment Period

1.5 years

First QC Date

April 28, 2014

Last Update Submit

December 1, 2015

Conditions

Keywords

amoxicillinpostpartum infectionspuerperal infection

Outcome Measures

Primary Outcomes (1)

  • Incidence of perineal wound infection

    Follow up perineal wound every day during admission and follow up 6 weeks after discharge

    within 6 weeks after normal labor

Study Arms (2)

Amoxicillin

EXPERIMENTAL

The patient will be received amoxicillin 500 mg 2 capsules orally bid pc for 5 days

Drug: Amoxicillin

Placebo

PLACEBO COMPARATOR

The patient will be received placebo 2 capsules orally bid pc for 5 days

Drug: Placebo

Interventions

The patient will be received amoxicillin 500 mg 2 capsules orally bid pc for 5 days

Also known as: Drug A, Drug B
Amoxicillin

The patient will be received placebo 2 capsules orally bid pc for 5 days

Also known as: Drug A, Drug B
Placebo

Eligibility Criteria

Age18 Years - 50 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Term pregnancy
  • Normal labor

You may not qualify if:

  • Penicillin allergy
  • Previous history antibiotic using within 2 weeks
  • Patients cannot take oral medication
  • Patients have underlying disease eg. diabetes mellitus, hypertension, HIV infection
  • Premature rupture of membranes

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Medicine Siriraj Hoapital Mahidol University

Bangkok, 10700, Thailand

Location

MeSH Terms

Conditions

Puerperal Infection

Interventions

Amoxicillin

Condition Hierarchy (Ancestors)

Pregnancy Complications, InfectiousInfectionsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesPuerperal Disorders

Intervention Hierarchy (Ancestors)

AmpicillinPenicillin GPenicillinsbeta-LactamsLactamsAmidesOrganic ChemicalsSulfur CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • Vitaya Titapant, MD

    Department of Obstetrics & Gynaecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 28, 2014

First Posted

May 6, 2014

Study Start

May 1, 2014

Primary Completion

November 1, 2015

Study Completion

November 1, 2015

Last Updated

December 3, 2015

Record last verified: 2015-12

Locations